TD Asset Management Inc boosted its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report) by 172.7% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,000 shares of the specialty pharmaceutical company’s stock after acquiring an additional 9,500 shares during the period. TD Asset Management Inc’s holdings in Collegium Pharmaceutical were worth $483,000 at the end of the most recent quarter.
Several other institutional investors have also added to or reduced their stakes in COLL. Gladius Capital Management LP bought a new stake in Collegium Pharmaceutical in the second quarter valued at approximately $32,000. Principal Securities Inc. bought a new stake in Collegium Pharmaceutical in the fourth quarter valued at approximately $40,000. nVerses Capital LLC boosted its holdings in Collegium Pharmaceutical by 1,600.0% in the second quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock valued at $55,000 after acquiring an additional 1,600 shares during the last quarter. Assetmark Inc. boosted its holdings in Collegium Pharmaceutical by 25.5% in the fourth quarter. Assetmark Inc. now owns 5,445 shares of the specialty pharmaceutical company’s stock valued at $168,000 after acquiring an additional 1,108 shares during the last quarter. Finally, Sheaff Brock Investment Advisors LLC bought a new position in shares of Collegium Pharmaceutical during the 1st quarter worth approximately $204,000.
Insider Activity at Collegium Pharmaceutical
In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the completion of the sale, the executive vice president now directly owns 120,161 shares of the company’s stock, valued at approximately $4,602,166.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 3.98% of the stock is currently owned by insiders.
Analyst Upgrades and Downgrades
Check Out Our Latest Analysis on COLL
Collegium Pharmaceutical Price Performance
Shares of COLL opened at $37.50 on Monday. Collegium Pharmaceutical, Inc. has a 12-month low of $20.95 and a 12-month high of $40.95. The business’s fifty day moving average is $35.43 and its 200 day moving average is $35.40. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. The stock has a market cap of $1.21 billion, a P/E ratio of 15.63 and a beta of 0.94.
Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) last issued its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a return on equity of 107.62% and a net margin of 17.32%. The company had revenue of $145.28 million for the quarter, compared to analysts’ expectations of $143.94 million. During the same period last year, the business earned $1.13 EPS. Collegium Pharmaceutical’s quarterly revenue was up 7.2% compared to the same quarter last year. Sell-side analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.82 earnings per share for the current fiscal year.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Further Reading
- Five stocks we like better than Collegium Pharmaceutical
- How to Read Stock Charts for Beginners
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- How to Buy Cheap Stocks Step by Step
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- Using the MarketBeat Dividend Yield Calculator
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Free Report).
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.